Tesamorelin comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-06-10. Numbers and descriptions here follow the published literature rather than marketing material.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized cake in single-use vials |
| Solubility class | Freely soluble in water | Reconstituted with sterile diluent before injection |
| Typical storage temperature | 2 to 8 degrees Celsius | Before reconstitution; protect from light |
| Typical analytical method | Reversed-phase high-performance liquid chromatography | Purity and related-substance testing |
| Identity confirmation | Mass spectrometry | Observed mass near 5.1 kDa for the intact peptide |
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
=== Hydromorphone === Hydromorphone is derived from morphine and may be used as an alternative to it. It has a high first-pass metabolism when given orally, and is primarily glucuronidated in the liver to hydromorphone-3-glucoronide (H3G). 75% of hydromorphone is renally excreted, with 7% excreted as the parent opiate.
Aircraft de-icing: An 80 grams (2.8 oz) carbon nanotube aerogel could cover the wings of a jumbo jet. Aerogel heaters could operate continuously at low power, preventing ice from forming. Catalyst or catalyst carrier. Chemical adsorber: Silica aerogels have high surface area, porosity, and are ultrahydrophobic. They may be used to remove heavy metals, for example in wastewater treatment. Cosmic dust capture: NASA used aerogel to trap space dust particles aboard the Stardust spacecraft. The particles vaporize on impact with solids and pass through gases, but can be trapped in aerogels. NASA also used aerogel for thermal insulation for the Mars rovers. Drug delivery: Drugs can be adsorbed from supercritical CO2 with release rate controlled by varying the aerogel properties. Electrochemical double layer supercapacitors. Aerogels' high surface area allow capacitors that are .02-.05% the size of similarly rated electrolytic capacitors. Electromagnetic shielding Energy absorbers Fuel cells: platinum-on-carbon catalysts. Imaging devices, optics, and light guides. Impedance matchers for transducers, speakers and range finders. Inertial Confinement Fusion (ICF) and X-ray laser targets: In ICF, it is used as low-density target materials to create foam targets that aid in simulating the conditions necessary for fusion. Their low-density structure allows for precise control over the fusion fuel, facilitating efficient compression and heating by the laser energy. Introducing disorder into superfluid helium-3.
== History == The 1950s to 1970s represented the golden age of antibiotic discovery, where countless new classes of antibiotics were discovered to treat previously incurable diseases such as tuberculosis and syphilis. However, since that time the discovery of new classes of antibiotics has been almost nonexistent, and represents a situation that is especially problematic considering the resiliency of bacteria shown over time and the continued misuse and overuse of antibiotics in treatment. Already in 1940, in their letter to the editor of Nature journal, Abraham and Chain identified the enzyme penicillinase as responsible for the deactivation of penicillin in penicillin-resistant bacteria. This discovery was the first step in understanding the mechanisms of microbial resistance to β-lactam antibiotics. The phenomenon of antimicrobial resistance caused by overuse of antibiotics was predicted as early as 1945 by Alexander Fleming who said "The time may come when penicillin can be bought by anyone in the shops. Then there is the danger that the ignorant man may easily under-dose himself and by exposing his microbes to nonlethal quantities of the drug make them resistant." Without the creation of new and stronger antibiotics an era where common infections and minor injuries can kill, and where complex procedures such as surgery and chemotherapy become too risky, is a very real possibility. Antimicrobial resistance can lead to epidemics of enormous proportions if preventive actions are not taken.
In Inca mythology, a daughter of the earth mother Pachamama, Axomamma, is the goddess of potatoes. She ensured the fertility of the soil and the growth of the tubers. According to Iroquois mythology, the first potatoes grew out of Earth Woman's feet after she died giving birth to her twin sons, Sapling and Flint.
In December 2017, Tim Hortons opened two stores in the centre of Madrid and later opened another in the city of Pozuelo de Alarcón in the Community of Madrid. The menu also includes typical Spanish drinks apart from the typical drinks of a Tim Hortons.
Sources: en.wikipedia.org
==== Subsidies for Affordable Care Act ("Obamacare") ==== On January 8, 2026, the House voted 230–196 to extend the higher Biden-era subsidies for another three years. Without this extension, it's estimated that monthly premiums will double for many persons who are signed up for the Affordable Care Act. One House Republican said, "I am voting in favor of this discharge and of this legislation to send it to the Senate, so that the Senate will have the opportunity to put forth a reform package that can pass Congress and become law."
In July 2020, the UK government signed up for 60 million doses of a COVID-19 vaccine developed by GSK and Sanofi. It uses a recombinant protein–based technology from Sanofi and GSK's pandemic technology. The companies claimed to be able to produce one billion doses, subject to successful trials and regulatory approval, during the first half of 2021. The company also agreed to a $2.1 billion deal with the United States to produce 100 million doses of the vaccine.
The main drawback to using MALBAC is that it has reduced accuracy compared to DOP-PCR and MDA due to the enzyme used to copy the DNA. Once amplified using any of the above techniques, the DNA can be sequenced using Sanger sequencing or next-generation sequencing (NGS).
On some early frost-free models, the defrost limiter also sends a signal to the defrost timer to start the compressor and fan as soon as it shuts off the heating element before the timed defrost cycle ends. When the defrost cycle is completed, the compressor and fan are allowed to cycle back on. Frost-free refrigerators, including some early frost-free refrigerators/freezers that used a cold plate in their refrigerator section instead of airflow from the freezer section, generally don't shut off their refrigerator fans during defrosting. This allows consumers to leave food in the main refrigerator compartment uncovered, and also helps keep vegetables moist. This method also helps reduce energy consumption, because the refrigerator is above freeze point and can pass the warmer-than-freezing air through the evaporator or cold plate to aid the defrosting cycle.
SOCPAC and Southern Command pushed for a significant expansion of American assistance to the Filipino Counterterrorist effort, but being that Sulu was predominantly inhabited by Muslims and was the site where Islam was introduced to the Philippines, many members of both the Philippine and US governments believed that introducing American forces onto Sulu would have been met with intense resistance. Based on a PACOM assessment recommending such a deployment, the Secretary of Defense approved a second iteration of OEF-P to combat terrorism in the Southern Command Area of Responsibility, specifically on Sulu. SOCPAC established a larger JSOTF in Zamboanga and deployed aforce package to the island of Sulu, conducting operations based on the Basilan model. Using that template, SOCPAC deployed one ODB, 5 ODAs to Sulu to advise and assist AFP units in their effort to capture key terrorists. From October 2005 to July 2006, JSOTF-P units assisted Task Force (TF) Comet-the AFP command on Sulu-in setting conditions to deny terrorist sanctuary. ODAs advised their partner army and marine infantry battalions en route and area security to facilitate Filipino sponsored medical, veterinary, and engineer civilian action programs, along with various population engagement activities. These combined efforts succeeded in separating the terrorists from the population. On 27 October 2007, a U.S. Special Forces soldier from 2nd Battalion, 1st SFG was killed in an accidental drowning incident at Lake Seit in the southern Philippines. On 29 September 2009, a roadside bomb killed two U.S.
Sources: en.wikipedia.org
92A Automated Logistical Specialist 92F Petroleum Supply Specialist 92G Culinary Specialist 92L Petroleum Laboratory Specialist 92M Mortuary Affairs Specialist 92R Parachute Rigger 92S Shower/Laundry and Clothing Repair Specialist (RC) 92W Water Treatment Specialist 92Y Unit Supply Specialist 92Z Senior Noncommissioned Logistician
=== N05CM Other hypnotics and sedatives === N05CM01 Methaqualone N05CM02 Clomethiazole N05CM03 Bromisoval N05CM04 Carbromal N05CM05 Scopolamine N05CM06 Propiomazine N05CM07 Triclofos N05CM08 Ethchlorvynol N05CM10 Hexapropymate N05CM11 Bromides N05CM12 Apronal N05CM13 Valnoctamide N05CM15 Methylpentynol N05CM16 Niaprazine N05CM18 Dexmedetomidine N05CM20 Diphenhydramine N05CM22 Promethazine N05CM25 Magnesium aspartate hydrobromide N05CM26 Magnesium glutamate hydrobromide N05CM27 Doxylamine
== Studies == The accumulation ratio of a specific drug in humans is determined by clinical studies. According to a 2013 analysis, such studies are typically done with 10 to 20 subjects who are given one single dose followed by a washout phase of seven days (median), and then seven to 14 repeated doses to reach steady state conditions. Blood samples are drawn 11 times (median) per subject to determine the blood concentration of the studied drug.
== Notes == An α indicates the medicine is on the complementary list for which specialized diagnostic or monitoring or training is needed. An item may also be listed as complementary on the basis of higher costs or a less attractive cost-benefit ratio.
Sources: en.wikipedia.org
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.
The primary measure is usually a cross-sectional abdominal scan that separates internal fat from fat just under the skin. Waist circumference and body weight are recorded as secondary measures because they are easy to obtain but do not distinguish the two fat compartments. Hormone and metabolic blood tests are collected alongside the imaging.
Available follow-up data indicate that visceral fat drifts back toward pretreatment levels once injections stop. The change is therefore best described as treatment-dependent rather than permanent. Investigators continue to debate whether intermittent or repeated courses would preserve any benefit.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.